María-Pilar López-Garrido

María-Pilar López-Garrido

Auto-generated profile, based on publicly available information

María-Pilar López-Garrido

Genética Médica, Departamento de Ciencia y Tecnología Agroforestal y Genética, IDINE, UCLM, Albacete, Spain

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2013 in Ophthalmology
Verified
Journal Article
Closed access
MLMaría-Pilar López-Garrido
María-Pilar López-Garrido
CMCristina Medina-Trillo
Cristina Medina-Trillo
LMLaura Morales-Fernandez
Laura Morales-Fernandez
JGJulián García-Feijóo
Julián García-Feijóo
Jose M Martinez de la CasaJose M Martinez de la Casa
Jose M Martinez de la Casa
Julio EscribanoJulio Escribano
Julio Escribano

21 December 2009 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
MLM‐P López‐Garrido
M‐P López‐Garrido
CBC Blanco‐Marchite
C Blanco‐Marchite
FSF Sánchez‐Sánchez
F Sánchez‐Sánchez
ELE López‐Sánchez
E López‐Sánchez
VCV Chaqués‐Alepuz
V Chaqués‐Alepuz
Julio EscribanoJulio Escribano
Julio Escribano

23 February 2009
Verified
Journal Article
Open access
ECEzequiel Campos-Mollo
Ezequiel Campos-Mollo
MLMaría-Pilar López-Garrido
María-Pilar López-Garrido
CBCristina Blanco-Marchite
Cristina Blanco-Marchite
JGJulián García-Feijóo
Julián García-Feijóo
JPJesús Peralta
Jesús Peralta
Julio EscribanoJulio Escribano
Julio Escribano
To analyze the contributions of cytochrome P4501B1 (CYP1B1) mutations to primary congenital glaucoma (PCG) in Spanish patients. We analyzed, by polymerase chain reaction (PCR) DNA sequencing, the presence of promoter (−1 to −867) and exon CYP1B1 mutations in 38 unrelated Spanish probands affected by PCG. Functional analysis of nine identified mutations was performed measuring ethoxyresorufin O-deethylation activity and CYP1B1 stability in transiently transfected human embryonic kidney 293T (HEK-293-T) cells. We found a total of 16 different mutations in 13 (34.2%) index cases. The identified mutations included nine missense and three nonsense nucleotide changes, three small deletions, and a short duplication. Eleven probands were compound heterozygotes and two were heterozygotes. Six of the identified mutations were novel (A106D, E173X, F261L, E262X, W341X, and P513_K514del). Mutations T404fsX30 and R355fsX69 were the most prevalent among index cases and were detected in six (23.0%) and three (11.5%) patients, respectively. Functional analysis showed that the three nonsense mutants assayed (E173X, E262X, and W341X) and F261L were null alleles. Of the remaining mutants, four (P52L, G61E, Y81N, and E229K) showed catalytic activities ranging from 20% to 40% of wild-type CYP1B1 and high protein instability. Mutation P400S showed normal catalytic activity and moderate instability. These five mutants were classified as hypomorphic alleles. Patients carrying two null alleles showed severe phenotypes featured by very early PCG onset usually at birth or in the first month of life (0.6±0.9 months). Incomplete penetrance was detected in patients carrying hypomorphic alleles. Our data indicate that approximately one-third of Spanish patients with PCG carry loss-of-function CYP1B1 and show that null alleles are associated with the most severe phenotypes. Hypomorphic alleles may contribute to some cases of incomplete penetrance.

11 July 2006
Verified
Journal Article
Closed access
MLMaría-Pilar López-Garrido
María-Pilar López-Garrido
FSFrancisco Sánchez-Sánchez
Francisco Sánchez-Sánchez
FLFrancisco López-Martínez
Francisco López-Martínez
Jose Daniel Aroca-AguilarJose Daniel Aroca-Aguilar
Jose Daniel Aroca-Aguilar
CBCristina Blanco-Marchite
Cristina Blanco-Marchite
Julio EscribanoJulio Escribano
Julio Escribano

1 October 2011 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Closed access
PDF file
CBCristina Blanco-Marchite
Cristina Blanco-Marchite
FSFrancisco Sánchez-Sánchez
Francisco Sánchez-Sánchez
MLMaría-Pilar López-Garrido
María-Pilar López-Garrido
MIMercedes Iñigez-De-Onzoño
Mercedes Iñigez-De-Onzoño
FLFrancisco López-Martínez
Francisco López-Martínez
Julio EscribanoJulio Escribano
Julio Escribano
Purpose.: To investigate the role of WDR36 and P53 sequence variations in POAG susceptibility. Methods.: The authors performed a case-control genetic association study in 268 unrelated Spanish patients (POAG1) and 380 control subjects matched for sex, age, and ethnicity. WDR36 sequence variations were screened by either direct DNA sequencing or denaturing high-performance liquid chromatography. P53 polymorphisms p.R72P and c.97–147ins16bp were analyzed by single-nucleotide polymorphism (SNP) genotyping and PCR, respectively. Positive SNP and haplotype associations were reanalyzed in a second sample of 211 patients and in combined cases (n = 479). Results.: The authors identified almost 50 WDR36 sequence variations, of which approximately two-thirds were rare and one-third were polymorphisms. Approximately half the variants were novel. Eight patients (2.9%) carried rare mutations that were not identified in the control group (P = 0.001). Six Tag SNPs were expected to be structured in three common haplotypes. Haplotype H2 was consistently associated with the disease (P = 0.0024 in combined cases). According to a dominant model, genotypes containing allele P of the P53 p.R72P SNP slightly increased glaucoma risk. Glaucoma susceptibility associated with different WDR36 genotypes also increased significantly in combination with the P53 RP risk genotype, indicating the existence of a genetic interaction. For instance, the OR of the H2 diplotype estimated for POAG1 and combined cases rose approximately 1.6 times in the two-locus genotype H2/RP. Conclusions.: Rare WDR36 variants and the P53 p.R72P polymorphism behaved as moderate glaucoma risk factors in Spanish patients. The authors provide evidence for a genetic interaction between WDR36 and P53 variants in POAG susceptibility, although this finding must be confirmed in other populations.

1 February 2012 in Journal of Urology
Verified
Journal Article
Closed access
ASAntonio S. Salinas-Sánchez
Antonio S. Salinas-Sánchez
MDMaría J. Donate-Moreno
María J. Donate-Moreno
MLMaría-Pilar López-Garrido
María-Pilar López-Garrido
JGJosé M. Giménez-Bachs
José M. Giménez-Bachs
Julio EscribanoJulio Escribano
Julio Escribano
CYP1B1 activates procarcinogens in some human tissues, including the urinary tract. Changes related to genetic polymorphisms are a known risk factor for cancer. We analyzed the association between CYP1B1 sequence variations and bladder cancer. Sequence variations in the coding region (exons 2 and 3) and the neighboring introns of CYP1B1 were analyzed by direct polymerase chain reaction and DNA sequencing in 208 unrelated patients with bladder cancer and 208 healthy controls. We identified 6 known single nucleotide polymorphisms organized into 2 linkage disequilibrium blocks. The Ala/Ala and Leu/Val genotypes of the Ala119Ser and Leu432Val polymorphisms were significantly more common in patients than in controls (55.3% vs 42.8% and 54.8% vs 42.3%, respectively). The strongest individual single nucleotide polymorphism risk was found under an over dominant model for Leu432Val (OR 1.65, CI 95% 1.12-2.44). The 2 susceptibility single nucleotide polymorphisms were predicted to be structured into 4 haplotypes and more than 10 diplotypes. No individual haplotype was associated with bladder cancer but the diplotype Ala-Leu/Ala-Val was significantly overrepresented in cases compared to controls (31.73% vs 17.31%, OR 2.22, 95% CI 1.36-3.62, p = 0.001). The OR was approximately 1.6 for the individual genotypes Ala/Ala and Leu/Val, which increased to 2.2 for the Ala-Leu/Ala-Val diplotype. A risk occupation had a modifying effect, increasing the crude OR of the combined genotype Ala/Ala + Leu/Val from 2.2 to 8.3. This study provides strong evidence for the role of common CYP1B1 variants as risk factors for bladder cancer, which increases with occupational exposure.